IGI Logo

Avio Smart Market Stack is currently trading at Rs. 9.07, up by 0.03 points or 0.33% from its previous closing of Rs. 9.04 on the BSE.

The scrip opened at Rs. 9.04 and has touched a high and low of Rs. 9.39 and Rs. 8.98 respectively. So far 436768 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 19.00 on 24-Apr-2025 and a 52 week low of Rs. 8.80 on 05-Mar-2026.

Last one week high and low of the scrip stood at Rs. 11.27 and Rs. 8.80 respectively. The current market cap of the company is Rs. 275.95 crore.

The promoters holding in the company stood at 69.37%, while Institutions and Non-Institutions held 1.90% and 28.74% respectively.

Avio Smart Market Stack (ASMS) has initiated an expanded collaboration with Huwel Lifesciences (Huwel) to introduce a range of patented molecular diagnostic products across multiple healthcare segments in India. The development follows the recently signed Shareholders’ Agreement between the two companies, under which they aim to jointly scale advanced diagnostic technologies and bring them to institutional and healthcare markets across the country.

Huwel has developed multiple patented diagnostic technologies and is building a strong pipeline of new products, with several additional patents and platforms currently under development. The company’s capabilities span RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels. Research, assay development, and manufacturing are carried out within Huwel’s own facilities. Huwel’s molecular diagnostic solutions are designed to enable rapid and cost-efficient tuberculosis detection using open RT-PCR systems, allowing tests to run on RT-PCR laboratory infrastructure that was widely deployed across the country during the COVID-19 pandemic. This approach enables scalable public health testing without requiring significant new infrastructure investments.

The company’s tuberculosis molecular diagnostic platform has already received the necessary regulatory approvals and validations. Building on the same technology platform, Huwel has also developed molecular diagnostics for HIV, HPV-based cervical cancer screening, antimicrobial resistance (AMR) surveillance, hepatitis, and several other infectious diseases, using scalable open RT-PCR systems suitable for large-scale testing. As part of the collaboration, the company will support the go-to-market strategy, institutional engagement, and commercialization of these technologies by leveraging its institutional relationships, digital infrastructure capabilities, and experience in executing large-scale programs.